Get started
Author

Hao Sun

Observed name: Sun, Hao
Observed institutions: Sun Yat-sen University, Beijing University of Chinese Medicine, Capital Medical University, Fudan University, Kunming Medical University, University of Michigan, Bristol-Myers Squibb (United States), Nanjing Drum Tower Hospital, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Zhongshan Hospital, Jiangsu Province Hospital, Xijing Hospital, Nanjing Institute of Environmental Sciences, Guangzhou Laboratory, Henan Medical University, Nanjing Medical University, Xi'an Jiaotong University, Nanjing University, Air Force Medical University
ORCID: 0009-0004-2698-341X
Observed ORCID: 0009-0004-2698-341X
OpenAlex ID: A5101239088
Metabolic Reprogramming of Microglia in Sepsis-Associated Encephalopathy: Insights from Neuroinflammation
2022 · Shenjia Gao, Yi Jiang, et al. · Current Neuropharmacology · 46
PDF
Progress and application of adipose-derived stem cells in the treatment of diabetes and its complications
2024 · Dongxu Yan, Yujie Song, et al. · Stem Cell Research & Therapy · 33
PDF
N-acetyltransferase 10 mediates cognitive dysfunction through the acetylation of GABA B R1 mRNA in sepsis-associated encephalopathy
2024 · Shenjia Gao, Ruling Shen, et al. · Proceedings of the National Academy of Sciences · 30
Single‐Cell Landscape of Bronchoalveolar Lavage Fluid Identifies Specific Neutrophils during Septic Immunosuppression
2025 · Rong Shen, Yi Jiang, et al. · Advanced Science · 21
Targeting NEDD8 suppresses surgical stress-facilitated metastasis of colon cancer via restraining regulatory T cells
2024 · Yi Jiang, Shenjia Gao, et al. · Cell Death and Disease · 21
PDF
Fibrinogen-to-albumin ratio predicts overall survival of hepatocellular carcinoma
2023 · Hao Sun, Jie Ma, et al. · World Journal of Gastrointestinal Oncology · 19
Prognostic value of tertiary lymphoid structures (TLS) in digestive system cancers: a systematic review and meta-analysis
2023 · Hao Sun, Yuanyu Shi, et al. · BMC Cancer · 16
PDF
SiRNA-HIF-1α delivered by attenuated Salmonella enhances the efficacy of Lenvatinib against hepatocellular carcinoma
2024 · Pengfei Chen, Yanling Wang, et al. · International Immunopharmacology · 11
Emerging nanomedicine for liver diseases treatment
2025 · Yawen Zhu, Dongxue Ge, et al. · Journal of Nanobiotechnology · 6
PDF
Spatial distribution, potential sources, and dry deposition fluxes of per- and polyfluoroalkyl substances (PFAS) in atmospheric particles (PM2.5) in the offshore eastern China sea (OECS)
2025 · Hao Sun, Shuai Sun, et al. · Atmospheric Environment · 6
Synergistic effects of resveratrol with gemcitabine in pancreatic cancer chemotherapy by inhibiting the c-Met/PARP1 axis
2023 · Shuai Wu, Jiaqiang Ren, et al. · Journal of Pancreatology · 4
Elucidation of the anti-β-cell dedifferentiation mechanism of a modified Da Chaihu Decoction by an integrative approach of network pharmacology and experimental verification
2023 · Hongdong Chen, Jing Guo, et al. · Journal of Ethnopharmacology · 4
Statistical operating characteristics of current early phase dose finding designs with toxicity and efficacy in oncology
2024 · Hao Sun, Hsin-Yu Lin, et al. · Journal of Biopharmaceutical Statistics · 2
PDF
Rapid identification of potential nonsteroidal anti‐inflammatory drug overdose–induced liver toxicity and prediction of follow‐up exposure: Integrating bioanalytical and population pharmacokinetic assay
2024 · Sufeng Zhou, Tangping Zhao, et al. · Biomedical Chromatography · 2
Phase 1b OMNIVERSE trial: Safety and tolerability of oral azacitidine (Oral-AZA) in combination with venetoclax (VEN) for treatment of acute myeloid leukemia.
2023 · Shaun Fleming, Gail J. Roboz, et al. · Journal of Clinical Oncology · 2
Effects of Bile Acid Receptor TGR5 Agonist INT-777 on Intestinal Microflora Abundance and Metabolites in Rats with Acute Pancreatitis
2024 · Ziyu Zhang, Yu Ji, et al. · SSRN Electronic Journal · 1
AML-370 Phase IB OMNIVERSE Trial: Safety and Tolerability of Oral Azacitidine (Oral-AZA) in Combination With Venetoclax (VEN) for Treatment of Acute Myeloid Leukemia (AML)
2023 · Shaun Fleming, Gail J. Roboz, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
PDF
An integrated single-cell atlas of human lung across the lifespan
2026 · Liangfeng Huang, Ziliang Huang, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Identification of Pyrrolo [2,3-b] Pyridine Derivatives as Novel JAK1 Inhibitors for the Treatment of Inflammatory Bowel Disease
2026 · Shuai Wen, Can Xiao, et al. · Molecules
Population-Level Amplicon and Metagenomic Analyses Uncover Distinct Effects of Landscape-Level Pesticides on the Maternal Gut Microbiome
2025 · Hongcheng Wei, Yifan Xu, et al. · Environment & Health
PDF
TITE-STEIN: Time-to-event Simple Toxicity and Efficacy Interval Design to Accelerate Phase I/II Trials
2025 · Sun, Hao, Tu, Jieqi, et al. · arXiv (Cornell University)
PDF
Occurrence and Dry Deposition Fluxes of Polycyclic Aromatic Hydrocarbons and Their Derivatives in the Bohai Sea Strait, China
2024 · Xinyuan Kang, Mian Li, et al. · SSRN Electronic Journal
POSTER: AML-370 Phase IB OMNIVERSE Trial: Safety and Tolerability of Oral Azacitidine (Oral-AZA) in Combination With Venetoclax (VEN) for Treatment of Acute Myeloid Leukemia (AML)
2023 · Shaun Fleming, Gail J. Roboz, et al. · Clinical Lymphoma Myeloma & Leukemia
PDF
P567: Phase 1b Omniverse Trial: Safety and Tolerability of Oral Azacitidine in Combination With Venetoclax for Treatment of Acute Myeloid Leukemia
2023 · Shaun Fleming, Gail Roboz, et al. · HemaSphere
Contributors
2023 · Ahmed Safwat Abouhashem, Aamir Ahmad, et al. · Elsevier eBooks
Works count: 28
Citation count: 225
H-index: 8
I10-index: 8
Year
Topic
Type